脑梗死，继心血管疾病后的第二大人类杀手，目前仍无有效的生化指标用于脑梗死的临床诊断，我们早期研究发现神经源性蛋白---胶质成熟因子-β（Glia maturation factor beta，GMFB）具备成为一项优异的化学标志物为脑梗死等疾病进行诊断的先决条件，作为一项新的生化检测指标，GMFB蛋白具有分子量小、特异性强、敏感性高及检测方法简便等优点。然而，在大脑梗死过程中GMFB蛋白能否通过血脑屏障释放至血液，GMFB蛋白作为脑梗死诊断指标的特异性和敏感性如何，以及其变化的具体分子机理如何？以上问题仍不明确，亟需解决。本研究采用免疫荧光染色、免疫组织化学染色、Live/Dead染色、ELISA检测、TTC染色、Micro-PET、体外缺血缺氧模型及大鼠脑梗死模型等新技术，在临床、动物及细胞三个水平上探究血清中游离GMFB蛋白升高的分子机理及其在脑梗死等疾病诊断中临床价值。

Cerebral infarction is the second largest causes leading to mortality in the world, and its incidence has increased year by year. Unlike the injury of the cardiac and liver tissues, there is no effective biochemical or immunological diagnostic indicators for cerebral infarction. Glia maturation factor beta, GMFB, is a small protein molecules specific expressed in the central nervous system of vertebrate and plays an important role in the regulation of neuron and glial cell growth and differentiation. Our early study showed that, as a kind of neurogenic protein, GMFB has the prerequisites to become an excellent chemical marker to diagnosis for cerebral infarction. As a novel biochemical indicator, GMFB protein has the following characteristics: the smaller molecular weight, stronger specificity, higher sensitivity and more easily detected, etc. However, it is still largely unknown whether GMFB expression can penetrate the blood brain barrier into the blood during brain infarction, and whether GMFB can be served as a novel indicator for the diagnosis of diseases such as brain injury. As a cerebral infarction indicator, the specificity and sensitivity of GMFB are still not clear and need to be solved, as well as its specific molecular mechanism of the change. In this study, we will explore its specific molecular mechanism of the change and assess the clinical diagnosis value of GMFB by immunofluorescence staining, immunohistochemistry staining, live/dead staining, ELISA analysis, TTC staining, micro-PET, nerve cell hypoxic-ischemic model and animal cerebral infarction model in the level of cell, animal and clinical patient.